SA521421595B1 - تركيبات وطرق لعلاج اضطرابات محسنة بتنشيط مستقبل مسكاريني - Google Patents
تركيبات وطرق لعلاج اضطرابات محسنة بتنشيط مستقبل مسكارينيInfo
- Publication number
- SA521421595B1 SA521421595B1 SA521421595A SA521421595A SA521421595B1 SA 521421595 B1 SA521421595 B1 SA 521421595B1 SA 521421595 A SA521421595 A SA 521421595A SA 521421595 A SA521421595 A SA 521421595A SA 521421595 B1 SA521421595 B1 SA 521421595B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- formulations
- methods
- receptor activation
- muscarinic receptor
- treating disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738333P | 2018-09-28 | 2018-09-28 | |
| PCT/US2019/053429 WO2020069301A1 (en) | 2018-09-28 | 2019-09-27 | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521421595B1 true SA521421595B1 (ar) | 2025-05-12 |
Family
ID=69945518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521421595A SA521421595B1 (ar) | 2018-09-28 | 2021-03-28 | تركيبات وطرق لعلاج اضطرابات محسنة بتنشيط مستقبل مسكاريني |
Country Status (30)
| Country | Link |
|---|---|
| US (8) | US10933020B2 (enExample) |
| EP (2) | EP3856182B1 (enExample) |
| JP (4) | JP7096441B2 (enExample) |
| KR (1) | KR102408292B1 (enExample) |
| CN (4) | CN115581696A (enExample) |
| AU (3) | AU2019346626B2 (enExample) |
| BR (1) | BR112021005802B1 (enExample) |
| CA (2) | CA3114623C (enExample) |
| CL (2) | CL2021000723A1 (enExample) |
| CO (1) | CO2021005261A2 (enExample) |
| CR (1) | CR20210212A (enExample) |
| DK (1) | DK3856182T3 (enExample) |
| EA (1) | EA202190356A1 (enExample) |
| ES (1) | ES3064063T3 (enExample) |
| FI (1) | FI3856182T3 (enExample) |
| HR (1) | HRP20260076T1 (enExample) |
| IL (3) | IL314873A (enExample) |
| LT (1) | LT3856182T (enExample) |
| MX (1) | MX391629B (enExample) |
| NZ (1) | NZ773719A (enExample) |
| PH (1) | PH12021550616A1 (enExample) |
| PL (1) | PL3856182T3 (enExample) |
| PT (1) | PT3856182T (enExample) |
| RS (1) | RS67749B1 (enExample) |
| SA (1) | SA521421595B1 (enExample) |
| SG (1) | SG11202102349PA (enExample) |
| SI (1) | SI3856182T1 (enExample) |
| SM (1) | SMT202600098T1 (enExample) |
| UA (1) | UA128017C2 (enExample) |
| WO (1) | WO2020069301A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2742728T3 (es) | 2009-07-22 | 2020-02-17 | PureTech Health LLC | Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico |
| PT3856182T (pt) * | 2018-09-28 | 2026-03-10 | Karuna Therapeutics Inc | Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos |
| JP2023503056A (ja) * | 2019-11-18 | 2023-01-26 | カルナ セラピューティックス，インコーポレイテッド | ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法 |
| AU2022226157A1 (en) * | 2021-02-24 | 2023-09-14 | Karuna Therapeutics, Inc. | Methods for treating disorders ameliorated by muscarinic receptor activation |
| CN117136048A (zh) * | 2021-02-24 | 2023-11-28 | 卡鲁娜治疗学有限公司 | 用于治疗由毒蕈碱受体激活所缓解的障碍的方法 |
| US20220370454A1 (en) * | 2021-05-18 | 2022-11-24 | Karuna Therapeutics, Inc. | Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics |
| CN120535517A (zh) * | 2022-06-14 | 2025-08-26 | 南京迈诺威医药科技有限公司 | 占诺美林的帕莫酸盐、晶型及其制备方法和用途 |
| US12269818B2 (en) | 2023-04-24 | 2025-04-08 | Terran Biosciences Inc. | Analogs of xanomeline |
| WO2025167860A1 (zh) * | 2024-02-06 | 2025-08-14 | 南京迈诺威医药科技有限公司 | 一种含有占诺美林或其盐的药物组合物 |
| CN118267380B (zh) * | 2024-05-31 | 2024-08-27 | 北京普诺旺康医药科技有限公司 | 呫诺美林-曲司氯铵缓释微球胶囊及其制备方法 |
| WO2025255488A2 (en) | 2024-06-06 | 2025-12-11 | Karuna Therapeutics, Inc. | Xanomeline quercetin complexes and trospium salts |
| WO2026064593A1 (en) | 2024-09-20 | 2026-03-26 | Karuna Therapeutics, Inc. | Method and compositions relating to the treatment of neuro-degenerative and psychiatric diseases |
| CN120983394B (zh) * | 2025-08-21 | 2026-08-04 | 广州共禾医药科技有限公司 | 一种具有多层核壳结构的双药共载口服微丸制剂及其制备方法与应用 |
| CN121695083A (zh) * | 2026-02-12 | 2026-03-20 | 纳索菲德(上海)制药技术有限公司 | 一种占诺美林的鼻脑递释制剂 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4647580A (en) | 1985-07-18 | 1987-03-03 | Syntex (U.S.A.) Inc. | Treatment of Alzheimer's disease |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| US5480651A (en) | 1992-03-16 | 1996-01-02 | Regents Of The University Of California | Composition and method for treating nicotine craving in smoking cessation |
| PT734259E (pt) * | 1993-08-19 | 2002-11-29 | Novo Nordisk As | Utilizacao de derivados de piperidina para o tratamento da esquizofrenia |
| US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| JP2000515213A (ja) | 1996-01-19 | 2000-11-14 | ラファエル、ピーター、ロバート | 三サイクルエンジン |
| DE19612504C2 (de) | 1996-03-29 | 2003-10-23 | Boehringer Ingelheim Kg | Neue Wirkstoffkompositionen |
| GB9612710D0 (en) | 1996-06-18 | 1996-08-21 | Pfizer Ltd | Method of treatment |
| EP0821958A3 (en) | 1996-08-01 | 1998-07-08 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression |
| EP0821959A3 (en) | 1996-08-01 | 1998-09-16 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal |
| EP0821954A1 (en) | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating mental retardation |
| EP0821956A1 (en) | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating disruptive behavior disorders |
| EP0821955B1 (en) | 1996-08-01 | 2002-02-20 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder |
| EP0821957A3 (en) | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse |
| WO1998030243A1 (en) | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| KR20010072784A (ko) | 1998-08-18 | 2001-07-31 | 지. 카파트 | 무스카린성 작용제 및 길항제 |
| WO2001062236A2 (en) | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| WO2002003684A2 (en) | 2000-06-30 | 2002-01-10 | Eli Lilly And Company | Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| CA2432543A1 (en) | 2000-12-22 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Combination drugs |
| US6862890B2 (en) * | 2001-01-30 | 2005-03-08 | Board Of Regents, University Of Texas System | Process for production of nanoparticles and microparticles by spray freezing into liquid |
| US20040023951A1 (en) | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| US20040224012A1 (en) | 2001-10-05 | 2004-11-11 | Pichit Suvanprakorn | Topical application and methods for administration of active agents using liposome macro-beads |
| WO2003030818A2 (en) | 2001-10-05 | 2003-04-17 | Pichit Suvanprakorn | Active agents using liposome beads |
| PL207038B1 (pl) * | 2002-01-25 | 2010-10-29 | Theravance | Podstawione pochodne kwasu fenylooctowego, związek pośredni, kompozycja farmaceutyczna zawierająca te pochodne oraz ich zastosowanie |
| WO2004060347A2 (en) | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
| US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| JP4584706B2 (ja) | 2002-05-03 | 2010-11-24 | イスラエル インスティチュート フォー バイオロジカル リサーチ | 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物 |
| US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| US20050250767A1 (en) | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US20050085463A1 (en) | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| GB0307860D0 (en) | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
| JP5547865B2 (ja) | 2003-10-29 | 2014-07-16 | ワイス・エルエルシー | アプリンドルおよびその誘導体を含む持続放出型医薬組成物 |
| DE602004030931D1 (enExample) | 2003-11-04 | 2011-02-17 | Supernus Pharmaceuticals Inc | |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| BRPI0417749A (pt) | 2003-12-22 | 2007-04-10 | Acadia Pharm Inc | composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| JP2008504372A (ja) | 2004-06-18 | 2008-02-14 | ニューロケム （インターナショナル） リミティッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| GB0428170D0 (en) | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Mono and Combination Therapy |
| GB0428180D0 (en) | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Combination therapy |
| WO2006086698A2 (en) | 2005-02-11 | 2006-08-17 | Stephen Wills | Treating microvasculature diseases with acetyl cholinesterase inhibitors |
| JP4732769B2 (ja) | 2005-03-04 | 2011-07-27 | 富士フイルム株式会社 | 内視鏡装置 |
| TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| US7759353B2 (en) | 2005-06-14 | 2010-07-20 | Schering Corporation | Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment |
| US7390816B2 (en) | 2005-06-21 | 2008-06-24 | Bridge Pharma, Inc. | Methods for treating urinary incontinence in patients suffering from memory disorders |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| RU2435610C2 (ru) | 2005-09-02 | 2011-12-10 | Теравида, Инк. | Терапия для лечения заболевания |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| GB0607946D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607949D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607952D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
| TW200811105A (en) | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| AU2007247231B2 (en) | 2006-05-04 | 2012-05-31 | Solvay Pharmaceuticals B.V. | Muscarinic agonists to treat impulse control disorders |
| US7905852B2 (en) | 2006-05-16 | 2011-03-15 | Barbara Jennings-Spring | Skin-contacting-adhesive free dressing |
| US8097633B2 (en) | 2006-11-15 | 2012-01-17 | Rich Steven A | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium |
| WO2008076287A2 (en) | 2006-12-13 | 2008-06-26 | Tuel Stephen M | Methods of making pharmaceutical components for customized drug products |
| GB0702385D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
| GB0702416D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
| GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
| GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| GB0703999D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | New combination 667 |
| EP2141992A1 (en) | 2007-03-29 | 2010-01-13 | Merck & Co., Inc. | Combination therapy for the treatment-of lower urinary tract symptoms |
| CL2008001970A1 (es) * | 2007-07-03 | 2009-03-27 | Synthon Bv | Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva. |
| US20100329996A1 (en) | 2007-09-12 | 2010-12-30 | Glaxo Group Limited | Novel Combination of Therapeutic Agents |
| WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
| NO2200610T3 (enExample) | 2007-09-21 | 2018-06-09 | ||
| TWI454288B (zh) | 2008-01-25 | 2014-10-01 | Gruenenthal Chemie | 藥物劑型 |
| EP4088717A1 (en) | 2008-03-27 | 2022-11-16 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
| WO2009132239A2 (en) | 2008-04-24 | 2009-10-29 | Trustees Of Boston University | A network biology approach for identifying targets for combination therapies |
| GB0822077D0 (en) | 2008-12-03 | 2009-01-07 | Minster Res Ltd | Novel treatments |
| WO2010102218A1 (en) | 2009-03-05 | 2010-09-10 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| US10265311B2 (en) * | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| ES2742728T3 (es) | 2009-07-22 | 2020-02-17 | PureTech Health LLC | Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico |
| WO2011085406A1 (en) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| GB2479213B (en) | 2010-04-01 | 2013-07-10 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
| WO2012033956A1 (en) | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
| AU2012253669A1 (en) * | 2011-05-10 | 2013-11-28 | Theravida, Inc. | Combinations of trospium and salivary stimulants for the treatment of overactive bladder |
| CA2835293C (en) | 2011-06-08 | 2020-08-18 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| AU2013312749B2 (en) | 2012-09-05 | 2018-01-18 | Chase Pharmaceuticals Corporation | Anticholinergic neuroprotective composition and methods |
| US10307409B2 (en) | 2015-03-06 | 2019-06-04 | Chase Pharmaceuticals Corporation | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system |
| EP3265466A4 (en) | 2015-03-06 | 2018-12-26 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
| EP3265067A4 (en) | 2015-03-06 | 2018-09-12 | Chase Pharmaceuticals Corporation | Oxybutynin-xanomeline transdermal therapeutic system combinations |
| JP6566254B2 (ja) | 2015-08-21 | 2019-08-28 | セイコープレシジョン株式会社 | フォーカルプレーンシャッタおよび光学機器 |
| UA125747C2 (uk) * | 2015-09-01 | 2022-06-01 | Фьост Вейв Байо, Інк. | Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю |
| CA2996719A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system |
| CL2018000559A1 (es) | 2015-10-14 | 2018-08-17 | First Wave Bio Inc | Métodos y composiciones para tratar condiciones asociadas con respuestas inflamatorias anormales |
| KR102600541B1 (ko) | 2016-01-20 | 2023-11-08 | 테라비다, 인코포레이티드 | 다한증을 치료하기 위한 방법 및 조성물 |
| WO2017147104A1 (en) | 2016-02-24 | 2017-08-31 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combinations |
| JP7197472B2 (ja) | 2017-05-19 | 2022-12-27 | 武田薬品工業株式会社 | スクリーニング方法 |
| MX2020010993A (es) | 2018-04-19 | 2020-12-09 | Ucar Health Gmbh | Propiedades antimicrobianas para superficies, aire, textiles, pinturas, plasticos, silicona, madera, polietileno, metales y sus derivados. |
| PT3856182T (pt) | 2018-09-28 | 2026-03-10 | Karuna Therapeutics Inc | Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos |
| US20210145804A1 (en) | 2019-11-18 | 2021-05-20 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
| JP2023503056A (ja) | 2019-11-18 | 2023-01-26 | カルナ セラピューティックス，インコーポレイテッド | ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法 |
| AU2022226157A1 (en) | 2021-02-24 | 2023-09-14 | Karuna Therapeutics, Inc. | Methods for treating disorders ameliorated by muscarinic receptor activation |
| US20220370454A1 (en) | 2021-05-18 | 2022-11-24 | Karuna Therapeutics, Inc. | Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics |
| US20250228832A1 (en) | 2022-04-07 | 2025-07-17 | Karuna Therapeutics, Inc. | Methods for treating disorders ameliorated by muscarinic receptor activation |
-
2019
- 2019-09-27 PT PT198655482T patent/PT3856182T/pt unknown
- 2019-09-27 CN CN202211404315.3A patent/CN115581696A/zh active Pending
- 2019-09-27 CN CN202511334149.8A patent/CN121513006A/zh active Pending
- 2019-09-27 CN CN202511334151.5A patent/CN121622680A/zh active Pending
- 2019-09-27 AU AU2019346626A patent/AU2019346626B2/en active Active
- 2019-09-27 ES ES19865548T patent/ES3064063T3/es active Active
- 2019-09-27 CR CR20210212A patent/CR20210212A/es unknown
- 2019-09-27 NZ NZ773719A patent/NZ773719A/en unknown
- 2019-09-27 SG SG11202102349PA patent/SG11202102349PA/en unknown
- 2019-09-27 FI FIEP19865548.2T patent/FI3856182T3/fi active
- 2019-09-27 IL IL314873A patent/IL314873A/en unknown
- 2019-09-27 UA UAA202100847A patent/UA128017C2/uk unknown
- 2019-09-27 KR KR1020217011501A patent/KR102408292B1/ko active Active
- 2019-09-27 WO PCT/US2019/053429 patent/WO2020069301A1/en not_active Ceased
- 2019-09-27 MX MX2021003621A patent/MX391629B/es unknown
- 2019-09-27 CN CN201980064585.4A patent/CN112789042A/zh not_active Withdrawn
- 2019-09-27 US US16/585,532 patent/US10933020B2/en active Active
- 2019-09-27 SM SM20260098T patent/SMT202600098T1/it unknown
- 2019-09-27 IL IL281809A patent/IL281809B/en unknown
- 2019-09-27 HR HRP20260076TT patent/HRP20260076T1/hr unknown
- 2019-09-27 PL PL19865548.2T patent/PL3856182T3/pl unknown
- 2019-09-27 IL IL295341A patent/IL295341B2/en unknown
- 2019-09-27 RS RS20260179A patent/RS67749B1/sr unknown
- 2019-09-27 LT LTEPPCT/US2019/053429T patent/LT3856182T/lt unknown
- 2019-09-27 EA EA202190356A patent/EA202190356A1/ru unknown
- 2019-09-27 SI SI201931014T patent/SI3856182T1/sl unknown
- 2019-09-27 CA CA3114623A patent/CA3114623C/en active Active
- 2019-09-27 CA CA3180743A patent/CA3180743A1/en active Pending
- 2019-09-27 EP EP19865548.2A patent/EP3856182B1/en active Active
- 2019-09-27 JP JP2021542064A patent/JP7096441B2/ja active Active
- 2019-09-27 DK DK19865548.2T patent/DK3856182T3/da active
- 2019-09-27 BR BR112021005802-8A patent/BR112021005802B1/pt active IP Right Grant
- 2019-09-27 EP EP25226537.6A patent/EP4729060A3/en active Pending
-
2020
- 2020-05-21 US US16/880,600 patent/US10925832B2/en active Active
-
2021
- 2021-01-07 US US17/143,904 patent/US11471413B2/en active Active
- 2021-02-04 US US17/167,714 patent/US20210154146A1/en not_active Abandoned
- 2021-03-18 PH PH12021550616A patent/PH12021550616A1/en unknown
- 2021-03-23 CL CL2021000723A patent/CL2021000723A1/es unknown
- 2021-03-28 SA SA521421595A patent/SA521421595B1/ar unknown
- 2021-05-05 CO CONC2021/0005261A patent/CO2021005261A2/es unknown
- 2021-11-30 CL CL2021003180A patent/CL2021003180A1/es unknown
-
2022
- 2022-02-03 US US17/649,826 patent/US11452692B2/en active Active
- 2022-02-09 JP JP2022018362A patent/JP7433351B2/ja active Active
- 2022-08-29 US US17/822,872 patent/US11890378B2/en active Active
- 2022-09-01 AU AU2022224813A patent/AU2022224813B2/en active Active
-
2023
- 2023-12-01 JP JP2023203693A patent/JP7676512B2/ja active Active
- 2023-12-21 US US18/392,891 patent/US12558317B2/en active Active
-
2024
- 2024-11-29 AU AU2024267020A patent/AU2024267020A1/en active Pending
-
2025
- 2025-04-30 JP JP2025075156A patent/JP2025118730A/ja active Pending
- 2025-09-25 US US19/340,263 patent/US20260102350A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550616A1 (en) | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
| MX2019001581A (es) | Inhibidores de ssao de aminopirimidina. | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
| EA201692487A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EP3256149A4 (en) | FORMULATION FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES | |
| CO2018000224A2 (es) | Compuestos inhibidores de la señalización de la vía de notch | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| MX390461B (es) | Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion | |
| CL2017003437A1 (es) | Formulación solida oral que contiene irinotecán y método de preparación de la misma | |
| CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| CO2019002517A2 (es) | Inhibidores de dopamina–β–hidroxilasa | |
| UY36123A (es) | Derivados de carboxamida | |
| EP4015001A4 (en) | Oral pharmaceutical composition | |
| IL290626A (en) | Tetracyclic compounds and their salts, compositions, and methods for their use | |
| EA201892098A1 (ru) | Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения | |
| BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
| EA201890896A1 (ru) | Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| ECSP18023544A (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona |